Dengue Literature Review

Dengue Clinical Classification

4 min read

Dengue Clinical Classification

Overview

Dengue illness is classified for clinical management and epidemiological surveillance purposes. Two WHO systems have been in use: the 1997 WHO classification (dengue fever / dengue haemorrhagic fever / dengue shock syndrome; DF/DHF/DSS) and the 2009 WHO classification (dengue without warning signs / dengue with warning signs / severe dengue). The 2009 system was designed to improve triage and early identification of patients at risk of progression to severe disease, and has largely replaced the 1997 system in clinical practice — though debate continues about which system is better suited to pathogenesis research.

Key Points from Literature

2009 WHO Classification (current)

Three categories:

  1. Dengue without warning signs: Fever + ≥2 of: nausea/vomiting, rash, aches/pains, positive tourniquet test, leukopenia; no warning signs present
  2. Dengue with warning signs: Any dengue + at least one warning sign — abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation (ascites, pleural effusion), mucosal bleed, lethargy/restlessness, liver enlargement >2 cm, rapid decrease in platelet count with rising haematocrit
  3. Severe dengue: Severe plasma leakage (DSS, fluid accumulation with respiratory distress); severe bleeding; severe organ impairment (liver, CNS, kidneys, heart) (see Guzman2016 - Dengue Infection)

Three clinical phases

  1. Febrile phase: Sudden high fever; headache; vomiting; rash; leukopenia; lasts 2–7 days
  2. Critical phase: Coincides with defervescence; plasma leakage, thrombocytopaenia nadir, haemostatic impairment; lasts 24–48 hours; most dengue deaths occur here
  3. Convalescent/reabsorption phase: Reabsorption of leaked plasma; risk of fluid overload if IV fluids not adjusted; bradycardia, rash common; occasional complications (encephalopathy, myocarditis)

2009 vs 1997 WHO system

  • 2009 system has greater discriminatory power for detecting patients at risk of progression and needing hospitalisation than the 1997 system
  • 1997 system: Some argue it was better at identifying plasma leakage (the key pathological process in DHF) and served as a better pathogenesis-research classifier; however, it misclassified approximately 32% of severe cases (classified as DF when they needed clinical intervention)
  • Expert consensus in La Habana, Cuba (2013): decrease in disease lethality documented after introduction of 2009 system
  • Some concerns: warning signs less useful in adults than children; high sensitivity but limited specificity → increased hospital admissions during epidemics (see Guzman2016 - Dengue Infection)

Diagnosis timeline and test selection

Day of illnessBest test
Day 1–5 (febrile)RT-PCR, virus isolation, NS1 antigen ELISA/rapid test
Day 5–6 onwardIgM ELISA (most widely used); IgG seroconversion (paired sera)
Any phasePRNT for definitive serology (reference lab)
  • Presumptive dengue diagnosis: positive IgM in a single sample, OR IgG titer ≥1,280 by HI or ELISA
  • Post-2015 complication: Zika virus (flavivirus) causes IgM cross-reaction with dengue serology; dual DENV/Zika testing now recommended where Zika is circulating

Contradictions & Debates

  • The 1997 system’s DHF/DSS categories were more precisely tied to the pathophysiological mechanism (plasma leakage) and may be more useful for research studies. The 2009 system’s “dengue with warning signs” category is clinically pragmatic but mechanistically broader.
  • Warning sign sensitivity/specificity in adults: several studies found warning signs less predictive in adults than children, potentially requiring age-stratified criteria.

Sources

  • Guzman2016 - Dengue Infection
  • Saito2004 - PAIgG and PAIgM in Secondary Dengue (applied 1997 WHO DHF criteria: platelet nadir <100,000/μl + haemorrhagic manifestations + haematocrit increase ≥20% or pleural effusion/ascites; DF defined by haematocrit increase <20% with no pleural effusion; cases graded DHF I–II [no shock]; exemplifies 1997 system in active research use)
  • Vo2020 - Autoantibody Profiling in Dengue (WHO 1997 classification used: 13 DF vs. 8 DHF hospitalised patients; Cambodia 2012–2013 cohort; all DHF cases secondary infection)
  • Pang2017 - DHF Pathogenesis Review (1997 WHO DHF/DSS classification used throughout; plasma leakage, thrombocytopenia, coagulopathy as cardinal DHF features; review, China)
  • Rajadhyaksha2012 - Dengue Evolving into SLE and Lupus Nephritis (1997 WHO DHF cardinal features cited in background discussion: increased vascular permeability, marked thrombocytopenia <100,000/mm³, fever 2–7 days, haemorrhagic tendency; Mumbai India; n=1 case report)
  • Jardim2012 - Autoimmune Features DHF Case Report (1997 WHO DHF criteria met: thrombocytopenia 95,000/mm³, plasma leakage evidence [triple serositis], altered haemostasis [DIC, fibrinogen 85.5 mg%], hepatic involvement [ALT 353/AST 370]; secondary DENV-3; Campinas Brazil; n=1 case report)
  • Chaturvedi2001 - Cytotoxic Factor Autoantibodies DHF (1997 WHO DHF grades I–IV applied to severity stratification of 136 patients from the 1996 North India epidemic; grades I–II [mild-moderate haemorrhage] vs III–IV [profound shock] used as the primary severity gradient against which anti-hCF autoantibody levels were compared; Lucknow + AIIMS New Delhi)
  • Farias2024 - Dengue Mimickers (clinical differential diagnosis review across all dengue severity levels; warning signs discussed in context of distinguishing dengue from mimickers including Still’s disease, SLE, ITP, acute abdomen; syndromic approach advocated for resource-limited settings; Brazil narrative review — secondary source)

Graph View

Backlinks